XML 63 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense is recognized in cost of revenues, corporate, technology and production systems, and selling, general, and administrative expense in the accompanying consolidated statements of operations and comprehensive income (loss) as follows:
Year Ended
December 31,
(in thousands)202320222021
Stock-based compensation expense
Cost of revenues$1,591 $1,533 $1,512 
Corporate technology and production systems2,822 2,264 2,054 
Selling, general and administrative30,237 20,008 29,014 
Total stock-based compensation expense$34,650 $23,805 $32,580 
Schedule of Weighted-Average Assumptions
The following table represents the weighted-average assumptions used to determine compensation costs and grant-date fair values for SVOs granted during the period presented:
Year Ended
December 31, 2021
Weighted-average assumptions used:
Expected volatility25.90 %
Risk-free interest rate0.60 %
Dividend rate0.00 %
Expected term, in years5.0
Weighted average grant date fair value$2.32 
The fair value for Options granted under the 2021 Equity Plan was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for periods presented:
Year Ended
December 31,
202320222021
Weighted-average assumptions used:
Expected volatility51.98 %45.03 %44.54 %
Risk-free interest rate4.18 %1.80 %1.07 %
Dividend rate0.00 %0.00 %0.00 %
Expected term, in years6.236.506.38
Weighted average grant date fair value$7.02 $10.43 $10.25 
Schedule of Share-based Payment Arrangement, Option, Activity
The table below provides a summary of SVOs and PSOs currently outstanding under the 2015 Plan for the year ended December 31, 2023:
Outstanding SVOsOutstanding PSOs
Number of
Shares		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life
(years)		Aggregate
Intrinsic
Value		Number of
Shares		Weighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life
(years)		Aggregate
Intrinsic
Value
(in thousands, except shares and per share amounts)
Balances at December 31, 20226,208,274 $9.59 5.00$36,513 3,081,855 $10.05 3.32$16,699 
Granted— — — — 
Forfeited / Expired— — — — 
Exercised(572,532)9.48 2,168 (44,925)9.68 148 
Balances at December 31, 2023(1)
5,635,742 $9.60 3.68$24,349 3,036,930 $10.05 2.14$11,732 
_________________________
(1)    All SVOs and PSOs are exercisable as of December 31, 2023.
The table below provides a summary of stock option activity under the 2021 Equity Plan for the year ended December 31, 2023:
Number of SharesWeighted Average Exercise PriceWeighted Average Contractual Term (in years)Aggregate Intrinsic Value
(in thousands, except shares and per share amounts)
Outstanding at December 31, 20224,387,501 $22.91 8.81$— 
Granted947,021 12.79 
Forfeited / Expired(776,323)20.95 
Exercised — — 
Outstanding at December 31, 20234,558,199 $21.14 8.06$904 
Exercisable at December 31, 20231,698,943 $22.98 7.76$— 
Schedule of Restricted Stock Activity
The table below provides a summary of restricted stock activity under the 2021 Equity Plan for the year ended December 31, 2023:
Number of SharesWeighted Average Fair Value
(per share)
Unvested at December 31, 20223,421,920 $20.32 
Granted2,266,296 12.48 
Forfeited / Cancelled(712,342)15.87 
Vested(1,179,671)20.57 
Unvested at December 31, 20233,796,203 $16.40 
The table below provides a summary of restricted stock unit activity under the 2021 Equity Plan for the year ended December 31, 2023:
Number of SharesWeighted Average Fair Value
(per share)
Unvested at December 31, 202251,249 $21.18 
Granted93,026 14.36 
Forfeited / Cancelled(3,351)18.09 
Vested(20,369)21.55 
Unvested at December 31, 2023120,555 $15.82